Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain

Brain Research

Volumn 1342, Issue , 2010, Pages 11-23

  Zhu, Hongwen ^a   O'Brien, Jennifer J ^a   O'Callaghan, James P ^b   Miller, Diane B ^b   Zhang, Qiang ^a   Rana, Minal ^a   Tsui, Tiffany ^a   Peng, Youyi ^a   Tomesch, John ^a   Hendrick, Joseph P ^a   Wennogle, Lawrence P ^a   Snyder, Gretchen L ^a  

^a Intra Cellular Therapies Inc   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

AChE inhibitor; DARPP 32; Muscarinic receptor; NR1; Phencynonate hydrochloride (PCH); Phospho specific antibody

Indexed keywords

AC 260584; CYCLIN DEPENDENT KINASE 5; DONEPEZIL; DYFLOS; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; OXOTREMORINE; PHENCYNONATE; PHOSPHOPROTEIN; SERINE; THREONINE; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EXPOSURE; FEMALE; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEIZURE;

ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; ISOFLUROPHATE; MICE; MICE, INBRED C57BL; MICROWAVES; NERVE TISSUE PROTEINS; PHOSPHORYLATION;

MUS;

EID: 77953289734     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.04.034     Document Type: Article

References (45)

1. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhardt J.E., Nelson R.B., and McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2910-2915
2. Barria A., Muller D., Derkach V., Griffeth L.C., and Soderling T.R. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 276 (1997) 2042-2045
3. Bibb J.A., Snyder G.L., Nishi A., Yan Z., Meijer L., Fienberg A.A., Tsai L.-H., Kwon Y.T., Girault J.-A., Czernik A.J., Huganir R.L., HCJr H., Nairn A.C., and Greengard P. Protein kinase and phosphatase control by distinct phosphorylation sites within a single regulatory protein. Nature 402 (1999) 669-671
4. Bymaster F.P., Carter P.A., Yamada M., Gomeza J., Wess J., Hamilton S.E., Nathanson N.M., McKinzie D.L., and Felder C.C. Role of specific muscarinic receptor subtypes in cholinergic parasympathetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. NeuroSci. 17 (2003) 1403-1410
5. Coe J.W., Brooks P.R., Vetelina M.G., Wirtz M.C., Arnold E.P., Huang J., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Heym J.H., Schaeffer E., Rollema H., Lu Y., Mansbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley III F.W., and O'Neill B.T. Varenicline: an a4B2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48 (2005) 3474-3477
6. Conn P.J., Jones C.K., and Lindsley C.W. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. TiPS 30 (2009) 148-155
7. DeCamilli P., Cameron R., and Greengard P. Synapsin I (protein I), a nerve terminal-specific phosphoprotein I: its general distribution in synapses of the central and peripheral nervous system demonstrated by immunofluorescence in frozen and plastic sections. J. Cell. Biol. 96 (1983) 1337-1354
8. 2+/calmodulin-kinase II enhances channel conductance of a-amino-3hydroxy-5-methyl-4-isoxazoleproprionate type glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3269-3274
9. Dudman J.T., Eaton M.E., Rajadhyaksha A., Macias W., Taher M., Barczak A., Kameyama K., Huganir R.L., and Konradi C. Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1. J. Neurochem. 87 (2003) 922-934
10. Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 9 (1995) 619-625
11. Fienberg A.A., Hiroi N., Mermelstein P., Song W.-J., Snyder G.L., Nishi A., Cheramy A., O'Callaghan J.P., Miller D., Cole D., Corbett R., Haile C., Cooper D., Onn S., Grace A.A., Ouimet C., White F.J., Hyman S.E., Surmeier D.J., Girault J.A., Nestler E., and Greengard P. DARPP-32, regulator of the efficacy of dopaminergic neurotransmission. Science 281 (1998) 838-842
12. Golomb B. Acetylcholinesterase inhibitors and Gulf War Illnesses. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4295-4300
13. Greengard P. The neurobiology of slow synaptic transmission. Science 294 (2001) 1024-1030
14. Hemmings Jr. H.C., Greengard P., Tung H.Y.L., and Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310 (1984) 503-505
15. Hogg R.C., Raggenbass M., and Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev. Physiol. Biochem. Pharmacol. 147 (2003) 1-46
16. Institute of Laboratory Animal Resources, 1996. Guide to the Care and Use of Laboratory Animals, National Academy Press, Washington, D.C.
17. Jovanovic J.N., Benfenati F., Siow Y.L., Sihra T.S., Sanghera J.S., Pelech S.L., Greengard P., and Czernik A.J. Neurotrophins stimulate phosphorylation of synapsin I by MAP kinase and regulate synapsin 1-actin interactions. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3679-3683
18. Jovanovic J.N., Sihra T.S., Nairn A.C., Hemmings Jr. H.C., Greengard P., and Czernik A.J. Opposing changes in phosphorylation of specific sites in synapsin I during Ca2+-dependent glutamate release in isolated nerve terminals. J. Neurosci. 21 (2001) 7944-7953
19. Lallement G., Carpentier P., Collet A., Pernot-Marino I., Baubichon D., and Blanchet G. Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus. Brain Res. 563 (1991) 234-240
20. Lallement G., Carpentier A., Collet D., Baubichon D., Pernot-Marino I., and Blanchet G. Extracellular acetylcholine changes in rat limbic structures during soman-induced seizures. NeuroToxicology 13 (1992) 556-568
21. Marlo J.E., Niswender C.M., Days E.L., Bridges T.M., Xiang Y., Rodriguez A.L., Shirey J.K., Brady A.E., Nalywajko T., Luo Q., Austin C.A., Williams M.B., Kim K., Williams R., Orton D., Brown H.A., Lindsley C.W., Weaver C.W., and Conn P.J. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. 75 (2009) 577-588
22. Matsubara M., Kusubata M., Ishiguro K., Uchida T., Titani K., and Taniguchi H. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. J. Biol. Chem. 35 (1996) 21108-21113
23. Mesulam M. The cholinergic lesion of Alzheimer's Disease: pivotal factor or side show?. Learn. Mem. 11 (2004) 43-49
24. Meyer D.A., Richer E., Benkovic S.A., Hayashi K., Kansy J.W., Hale C.F., Moy L.Y., Kim Y., O'Callaghan J.P., Tsai L.H., Greengard P., Nairn A.C., Cowan C.W., Miller D.B., Antich P., and Bibb J.A. Striatal dysregulation of Cdk5 alters locomotor responses to cocaine, motor learning, and dendritic morphology. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18561-18566
25. Miyaki K., Nishiwaki Y., Maekawa K., Ogawa Y., Asukai N., Yoshimura K., Etoh N., Matsumoto Y., Kikuchi Y., Kumagai N., and Omae K. Effects of sarin on the nervous system of subway workers sever years after the Tokyo subway sarin attack. J. Occup. Health 47 (2005) 299-304
26. Norrholm S.D., Bibb J.A., Nestler J.A., Ouimet C.C., Taylor J.R., and Greengard P. Cocaine-induced proliferation of dendritic spines in nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. Neurosci. 116 (2003) 19-22
27. Nozaki H., Hori S., Shinozawa S., Fujishima S., Takuma K., Sagoh M., Kimura H., Ohki T., Suzuki M., and Aikawa N. Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med. 21 (1995) 1032-1035
28. O'Callaghan J.P., and Sriram K. Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins. J. Neurosci. Methods 135 (2004) 159-168
29. Ouimet C.C., Miller P.E., Hemmings Jr. H.C., Walaas S.I., and Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci. 4 (1984) 111-124
30. Phillippens I.H., Melchers B.P., de Groot D.M., and Wolthuis O.L. Behavioral performance, brain histology, and EEG sequela after immediate combined atropine/diazepam treatment of soman-intoxicated rats. Pharmacol. Biochem. Behav. 42 (1992) 711-719
31. Racine R.J. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 32 (1972) 281-294
32. Ragozzino M.E., Mohler E.G., Prior M., Palencia C.A., and Rozman S. Acetylcholine levels in selective striatal regions promotes behavioral flexibility. Neurobiol. Learn. Mem. 91 (2009) 13-22
33. Roche K.W., O'Brien R.J., Mammen A.L., Bernhardt J., and Huganir R.L. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16 (1996) 1179-1188
34. Rohlman D.S., Lasarev M., Anger W.K., Scherer J., Stepfel J., and McCauley L. Neurobehavioral performance of adult adolescent agricultural workers. NeuroToxicology 28 (2007) 374-380
35. Scott D.B., Blanpied T.A., and Ehlers M.D. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45 (2003) 755-767
36. Shih T.M., Duniho S.M., and McDonough Jr. J.H. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 188 (2003) 69-80
37. Shih T.M., and McDonough Jr. J.H. Neurochemical mechanisms in soman-induced seizures. J. Appl. Toxicol. 17 (1997) 255-264
38. Snyder G.L., Fienberg A.A., Huganir R.L., and Greengard P. A dopamine/D1 receptor/PKA/DARPP-32/protein phosphatase-1 pathway regulates dephosphorylation of the N-methyl-d-aspartate receptor. J. Neurosci. 18 (1998) 10297-10303
39. Suzuki J., Kohno T., Tsukagosi M., Furuhata T., and Yamazaki K. Eighteen cases exposed to sarin in Matsumoto, Japan. Intern. Med. 36 (1997) 466-470
40. Taylor P. Anticholinesterase agents. In: Gilman A.G., Goodman L.S., Rall T.W., and Murad F. (Eds). The Pharmacological Basis of Therapeutics. 6th ed (1985), Macmillan, New York 110-129
41. Tingley W.G., Ehlers M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., and Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-d-Aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272 (1997) 5157-5166
42. Vanover K.E., Veinbergs I., and Davis R.E. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M1 receptor agonist, AC-260584. Behav. Neurosci. 122 (2008) 570-575
43. Wang L.Y., Wang Y., Zheng J.Q., Zhong B.H., Liu H., Dong S.J., Ruan J.X., and Liu K.L. Pharmacological profiles of an anticholinergic agent, phencynonate hydrochloride and its optical isomers. Acta Pharmacol. Sin. 26 (2005) 527-532
44. Wang Y.A., Zhou W.X., Li J.X., Liu Y.Q., Yue Y.J., Zheng J.Q., Liu K.L., and Ruan J.X. Anticonvulsant effects of phencynonate hydrochloride and other anticholinergic drugs in soman poisoning: neurochemical mechanisms. Life Sci. 78 (2005) 210-223
45. Yamagata Y., Jovanovic J.N., Czernik A.J., Greengard P., and Obata K. Bidirectional changes in synapsin I phosphorylation at MAP kinase-dependent sites by acute neuronal excitation in vivo. J. Neurochem. 80 (2002) 835-842